KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) EBIT Margin (2019 - 2025)

Esperion Therapeutics' EBIT Margin history spans 7 years, with the latest figure at 50.6% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 5699.0% year-over-year to 50.6%; the TTM value through Dec 2025 reached 14.95%, down 142.0%, while the annual FY2025 figure was 14.95%, 142.0% down from the prior year.
  • EBIT Margin reached 50.6% in Q4 2025 per ESPR's latest filing, up from 11.41% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 52.47% in Q1 2024 to a low of 1038.15% in Q1 2021.
  • Average EBIT Margin over 5 years is 167.06%, with a median of 106.21% recorded in 2023.
  • Peak YoY movement for EBIT Margin: soared 300782bps in 2021, then tumbled -19798bps in 2022.
  • A 5-year view of EBIT Margin shows it stood at 361.2% in 2021, then soared by 37bps to 225.92% in 2022, then soared by 42bps to 131.37% in 2023, then soared by 95bps to 6.4% in 2024, then skyrocketed by 891bps to 50.6% in 2025.
  • Per Business Quant, the three most recent readings for ESPR's EBIT Margin are 50.6% (Q4 2025), 11.41% (Q3 2025), and 8.61% (Q2 2025).